32 results about "Opioid withdrawal" patented technology

Compositions and methods for inhibiting opioid tolerance and opioid withdrawal-induced hyperalgesia are provided.

The present disclosure relates to the treatment of agitation or signs of agitation in certain human subjects, including subjects with a neurodegenerative, neuropsychiatric or opioid withdrawal disorder, by administering dexmedetomidine hydrochloride by the intravenous route.

The present invention provides a compound having the structure:or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with a pain, a depressive disorder, a mood disorder, an anxiety disorder, borderline personality disorder, opioid addiction, or opioid withdrawal symptoms by administering the compound to the subject.

The disclosure relates to a method of treating or preventing a condition in a subject associated with the activation of an opioid receptor in the periphery by administering an effective amount of 5-(2-methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide (Compound I). In particular, the disclosure relates to a method of treating or preventing opioid- induced constipation or opioid-induced bowel dysfunction in a human without reducing centrally-mediated opioid analgesia or producing central opioid withdrawal symptoms by administering an effective amount of Compound (I). The disclosure further relates to the use of Compound (I) for the preparation of a medicament for the treatment or prevention of a condition in a subject associated with the activation of an opioid receptor in the periphery.

Formulation comprising buprenorphine or a pharmaceutically acceptable salt thereof as the sole active ingredient, a viscosity enhancer, and a buffering agent in an amount to provide a pH of from 5.0 to 7.0 are useful for treating opioid withdrawal syndrome.

The present invention is directed to the treatment of chemical substance abuse and withdrawal symptoms, especially withdrawal symptoms associated with opioids, utilizing a combination of an effective amount of a cannabinoid, in particular, cannabidiol (CBD) and / or A9-tetrahydrocannabinol (THC) in combination with low dosage noribogaine or a derivative salt, solvate or ansolvate thereof to treat withdrawal symptoms, both acute and longer term. It has unexpectedly been discovered that the cannabinoids as described herein work in conjunction with noribogaine to synergistically ameliorate and / or attenuate chemical substance abuse, especially including opioid withdrawal symptoms, both acute and longer term symptoms, such that low dose noribogaine (often in daily dosages of 30 milligrams or less) may be favorably co-administered to a patient suffering from withdrawal symptoms, substantially shortening the QT interval of the patient and providing for a particularly safe and effective method to treat opioid withdrawal symptoms.

Formulations comprising buprenorphine are useful for treating opioid withdrawal syndrome.

The present invention relates to compositions and methods for managing opioid tolerance and reducing opioid withdrawal. More specifically, the present invention provides for endothelin, endothelin receptors, and endothelin receptor antagonists and agonists as a means for managing G-protein activity in the context of opioid tolerance and withdrawal.

A composition for treating opioid withdrawal and method of manufacture and administration of the composition creates a synergistic combination of cannabinoids, terpenoids, herbs, and medicinal mushrooms that help to eliminate the symptoms of opioid withdrawal by creating a medicinal entourage. The composition combines: between about 2.5 to 100 milligrams of a cannabinoid, between about 0.084 to 33.6 milligrams of a terpenoid, between about 0.5 to 3000 milligrams of an herb, and between about 25 to 2500 milligrams of a medicinal mushroom. The composition is orally administered in a lipid-enclosed capsule form. The terpenoid has a lipophilic nature that enhances the bioavailability of the cannabinoid. The herb works with the body's endocannabinoid system to enhance pain relief capacity of the cannabinoid, so as to help inhibit symptoms of opioid withdrawal. The medicinal mushroom comprises a psychedelic drug that creates a therapeutic effect with the cannabinoid to inhibit symptoms of opioid withdrawal.

A method of screening a compound or a composition for use in modulating opioid withdrawal symptoms in a mammal. The method comprises the steps of: selecting a group of test animals; separating the group into two subgroups; inducing pannexin -1 activation or expression in both subgroups; dosing a first subgroup with a candidate compound; dosing a second subgroup with a placebo; measuring ATP released in spinal microglia of test animals from both subgroups; quantifying the difference in ATP released in spinal microglia of test animals from the first subgroup and the second subgroup; if the difference in the ATP released in the first subgroup and the ATP released in the second subgroup is greater than 25%, then formulating the candidate compound into a pharmaceutical composition. Also disclosed, pharmaceutical compositions for modulating opioid withdrawal symptoms in a subject comprising a pannexin- 1 inhibitor. Said inhibitor may be lOpanx peptide with amino acid sequence WRQAAFVDS Y, mefloquine or probenecid.

The present invention provides a compound having the structure:or a pharmaceutically acceptable salt or ester thereof, and methods of using the compound to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorder, and opioid withdrawal symptoms.

A system comprises data processing hardware and memory hardware in communication with the data processing hardware, the memory hardware storing instructions that when executed on the data processing hardware cause the data processing hardware to perform operations comprising executing a prescription digital therapeutic configured to treat symptoms associated with opioid use disorder in a patient, wherein executing the prescription digital therapeutic comprises receiving a plurality of inputs associated with the patient from one or more of (i) first sensors associated directly with the patient and (ii) second sensors associated with a patient electronic device, wherein the plurality of inputs represent a level of opioid withdrawal associated with the patient, weighting the plurality of inputs associated with the patient to provide a plurality of weighted inputs, determining a recommended dosage of a buprenorphine-containing product for the patient based on the plurality of weighted inputs, and instructing an administration unit to administer the recommended dosage of the buprenorphine-containing product to the patient.

This invention relates to methods of treating, preventing, managing and / or controlling opioid withdrawal and / or a symptom associated with the opioid withdrawal. Compounds, compositions, medicaments and kits are provided that may be used in these methods.

Compositions and methods for inhibiting opioid tolerance and opioid withdrawal-induced hyperalgesia are provided.

A prodrug includes a pantothenate congener having an ester link with deltorphin I. The prodrug is administered to a patient in an amount effective to treat opioid withdrawal or other neurologic maladies.

Formulation comprising buprenorphine or a pharmaceutically acceptable salt thereof as the sole active ingredient, a viscosity enhancer, and a buffering agent in an amount to provide a pH of from 5.0 to 7.0 are useful for treating opioid withdrawal syndrome.

The present invention relates to methods of treating opioid dependence, enhancing the treatment of opioid dependence, treating opioid withdrawal, or alleviating one or more opioid withdrawal symptoms in a subject, preventing or reducing the likelihood of opioid dependence relapse in a subject treated for opioid dependence, reducing the vulnerability of a subject to develop opioid dependence in adulthood following opioid exposure during adolescence, or treating pain in a subject, comprising administering a therapeutically effective amount of a N-methyl-D-aspartate receptor (NMDA) partial agonist to the subject. The present invention further relates to compositions comprising an NMDA partial agonist for use with the aforementioned methods.

The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride. The composition has reduced side effects when compared with unconjugated hydrocodone.

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of motor neurone disease, diabetic neuropathy, postherpetic neuralgia, acute opioid withdrawal management, obsessive-compulsive disorder, premature ejaculation, PTSD, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, bipolar depression, depression, stress, cancer pain and lower back pain.

Formulation comprising buprenorphine or a pharmaceutically acceptable salt thereof as the sole active ingredient, a viscosity enhancer, and a buffering agent in an amount to provide a pH of from 5.0 to 7.0 are useful for treating opioid withdrawal syndrome.

The present invention provides an injectable liquid formulation with controlled release comprising: a) a lipid controlled-release matrix comprising at least 50% triacyl lipids; b) at least one oxygen containing organic solvent; c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention also provides a method for the treatment of pain, for opioid maintenance therapy or for the treatment of opioid dependence by detoxification and / or maintenance or for the treatment or prophylaxis of the symptoms of opioid withdrawal and / or cocaine withdrawal by injecting such a liquid composition.

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of motor neurone disease, diabetic neuropathy, postherpetic neuralgia, acute opioid withdrawal management, obsessive-compulsive disorder, premature ejaculation, PTSD, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, bipolar depression, depression, stress, cancer pain and lower back pain.

The current methods and compositions provide for a novel and effective therapeutic method for treating opioid use disorder, opioid withdrawal symptoms and / or chronic pain. Accordingly, certain aspects of the disclosure relate to a method for treating opioid use disorder, opioid withdrawal symptoms and / or chronic pain in a subject, the method comprising administering at least one purified cannabinoid compound and a partial opioid agonist. In some embodiments, the method comprises administering a composition comprising cannabidiol and buprenorphine.